Catequentinib
As of the edition of 20 October 2026, Catequentinib is a small molecule: in active development; acts on FLT4, KDR and KIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 425, 13 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route A because of this drug.
Companies on route A for this drug
In the product1 company-target row is on route A because of Catequentinib.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 35 | 3 | 9 | 0 |
| Phase 1 | 25 | 5 | 6 | 2 |
| Phase 2 | 302 | 38 | 101 | 10 |
| Phase 3 | 46 | 2 | 18 | 1 |
| Phase 4 | 17 | 1 | 9 | 0 |
| All trials | 425 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2011 to now |
| Cttq | Lead sponsor of trials | 2018 to now |
| Akeso | Lead sponsor of trials | 2018 to now |
| Sarcoma Oncology Research Center | Lead sponsor of trials | 2019 to now |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | Lead sponsor of trials | 2022 to now |
| Lyvgen Biopharma | Lead sponsor of trials | 2022 to now |